FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Disclosed is a composition for activating the growth of differentiated endothelial cells of the cornea, containing an effective amount of at least one of laminin 511, and/or laminin 521, and/or its functional fragment E8, which are expressed in endothelial cells of the cornea.
EFFECT: invention can be applied in medicine.
10 cl, 12 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW CORNEAL TREATMENT WITH LAMININ | 2015 |
|
RU2718062C2 |
| VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
| IMPROVED HUMANISED ANTIBODY TO HUMAN α9-INTEGRIN | 2009 |
|
RU2503720C2 |
| VASCULAR ADHESION PROTEIN-1 OF AMINOOXIDASE ACTIVITY | 1998 |
|
RU2204838C2 |
| THERAPEUTIC USE OF VEGF-C AND CCBE1 | 2014 |
|
RU2691104C2 |
| αvβ3 INTEGRIN SELECTIVE POLYPEPTIDES CONJUGATED WITH VARIANT OF HUMAN SERUM ALBUMIN (HSA), AND THEIR PHARMACEUTICAL APPLICATIONS | 2010 |
|
RU2547592C2 |
| POLYPEPTIDES DERIVED FROM TRYPTOPHANYL-TRNA-SYNTHETASE AND USES THEREOF IN CONTROLLING OF VASCULARISATION | 2002 |
|
RU2297425C2 |
| ANTI-Nogo ANTIBODIES ("11C7") AND THEIR APPLICATION IN PHARMACEUTICS | 2003 |
|
RU2350623C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING CANCER | 2009 |
|
RU2533460C2 |
| TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αβ-CAUSED ANGIOGENESIS | 1997 |
|
RU2195312C2 |
